IDEAYA Biosciences: $830M Cash, Two Offerings, EPS Miss
IDEAYA Biosciences missed Q2 2026 consensus EPS by 16.2%, its steepest quarterly shortfall in four quarters, against a $4.03 billion market cap priced on pipeline optionality. Two equity offerings exe
IDEAYA Biosciences Posts Second Straight EPS Miss
NEW YORK, August 28 —
IDEAYA Biosciences, Inc. (IDYA) posted a Q2 2026 EPS miss of 16.2%, the steepest shortfall in four quarters, raising an uncomfortable question: the $4.03 billion market cap still prices in a pipeline story, but the earnings trajectory no longer supports one. Two equity offerings in May and June 2026 while sitting on $830 million in cash sharpens the contradiction further.
- Q2 2026 EPS: -$1.22 vs. -$1.05 consensus, a 16.2% miss per the August 4 8-K
- $830M cash, $30M debt; trailing free cash flow: -$71M
- Chief Accounting Officer sold 9,550 shares at $40.01 on July 7, 2026 (per Form 4), within 4% of today's price
The Milestone That Wasn't an Inflection
Four quarters ago, IDEAYA reported EPS of $1.33 against a consensus estimate of -$0.55, a 341.9% positive surprise that looked, for a moment, like an operating breakthrough from a 145-person precision oncology company without a single approved product. It was almost certainly a collaboration milestone payment from one of IDEAYA's strategic partners, GlaxoSmithKline, Pfizer, Gilead Sciences, Novartis, or Jiangsu Hengrui Pharmaceuticals, rather than commercial momentum. The three quarters since have confirmed that reading: EPS went from a 0.6% beat to a 13.3% miss to the current 16.2% miss. The beat was a payment, not a turn.
Two Offerings, One Cash Pile, No Obvious Gap to Fill
IDEAYA filed a shelf registration and a 424B5 prospectus supplement on May 5, 2026, then executed a second equity offering on June 8 and 9, 2026, full exercise of the underwriters' option included. Both transactions happened against a balance sheet carrying roughly $800 million in net cash. Dilutive offerings when cash is abundant typically signal one of two things: management sees a capital-intensive catalyst coming that the current runway cannot fund, or the offering window was simply available and the board took it. Either reading lands differently depending on whether Darovasertib, the company's lead PKC inhibitor for uveal melanoma, generates the data needed to justify the spend. Trailing operating cash flow of -$112 million suggests the burn is real and accelerating.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| IDYA | $4.0B | n/a | +70.1% |
| CRNX | $9.0B | n/a | +173.8% |
| BCYC | $303M | n/a | -41.3% |
| KYMR | $9.9B | n/a | +191.8% |
| PCVX | $9.1B | n/a | +98.6% |
| MIRM | $6.1B | n/a | +35.0% |
What Resolves the Thesis
The number to watch is Darovasertib's progression across its metastatic, neoadjuvant, and adjuvant uveal melanoma trials, any readout that converts collaboration milestones into revenue would reframe the EPS trajectory. Secondary signals worth tracking: whether IDE849, the DLL3 antibody-drug conjugate targeting small-cell lung cancer, advances to a data-generating stage, and whether the CAO's July sale near current prices represents opportunistic liquidity or something more directional. Run the free IDEAYA Biosciences, Inc. deep-dive → for updated financials as trial results emerge. At a $4 billion valuation, the next earnings report will test whether the market still accepts pipeline optionality in place of results.
Current fundamentals, valuation and filing history for IDEAYA Biosciences, Inc. (IDYA) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What did IDEAYA report for Q2 2026 earnings?
IDEAYA reported Q2 2026 EPS of -$1.22 against a consensus estimate of -$1.05, a 16.2% miss per the August 4, 2026 8-K filing. That shortfall was the steepest in four quarters and follows a 13.3% miss the prior quarter.
Why did IDEAYA raise equity with $830 million in cash?
IDEAYA filed a shelf registration and a 424B5 prospectus supplement on May 5, 2026, then executed a second equity offering on June 8 and 9, 2026, both against a balance sheet carrying roughly $800 million in net cash. The article offers two readings: management may see a capital-intensive catalyst ahead that the current runway cannot fund, or the offering window was available and the board took it.
What caused IDEAYA's large EPS beat four quarters ago?
Four quarters prior, IDEAYA reported EPS of $1.33 against a consensus estimate of -$0.55, a 341.9% positive surprise. The article attributes this to a one-time collaboration milestone payment from a strategic partner such as GlaxoSmithKline, Pfizer, Gilead Sciences, Novartis, or Jiangsu Hengrui Pharmaceuticals, not commercial momentum.
What is darovasertib and what does it treat?
Darovasertib is IDEAYA's lead PKC inhibitor in trials for uveal melanoma, spanning metastatic, neoadjuvant, and adjuvant settings. A readout from those trials that converts collaboration milestones into durable revenue is described as the primary number that could reframe the company's EPS trajectory.
What did IDEAYA's chief accounting officer sell recently?
The Chief Accounting Officer sold 9,550 shares at $40.01 on July 7, 2026, per a Form 4 filing. The sale price was within 4% of the stock's price at the time the article was written.
IDEAYA Biosciences posted its second consecutive earnings miss in Q2 2026, with losses running 16% deeper than analyst estimates, just months after the precision oncology company conducted two separate equity offerings while already holding more than $800 million in cash.